SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

Search

UCB SA

Suletud

SektorTervishoid

169.85 0.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

168.75

Max

172.9

Põhinäitajad

By Trading Economics

Sissetulek

649M

857M

Müük

570M

3.4B

P/E

Sektori keskmine

30

50.291

Aktsiakasum

2.09

Dividenditootlus

0.88

Kasumimarginaal

25.498

Töötajad

9,052

EBITDA

704M

1.3B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.88%

2.40%

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-4.5B

31B

Eelmine avamishind

169.23

Eelmine sulgemishind

169.85

Uudiste sentiment

By Acuity

66%

34%

154 / 380 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. juuni 2025, 20:51 UTC

Tulu

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. juuni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. juuni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. juuni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. juuni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. juuni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. juuni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. juuni 2025, 18:39 UTC

Market Talk
Tulu

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. juuni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. juuni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. juuni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. juuni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. juuni 2025, 17:08 UTC

Tulu

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. juuni 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. juuni 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. juuni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. juuni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

154 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.